How to Spot Fake Tirzepatide and Semaglutide: A Filipino Buyer's Authentication Checklist

Counterfeit GLP-1 pens have been documented across the Philippines, Vietnam, Thailand, Malaysia, and Indonesia in increasing volume since late 2023. The combination of high demand, high retail price, and high margin on counterfeits has created a market with structural incentives for fakes. FDA Philippines (formerly BFAD) issued advisories on counterfeit branded tirzepatide and branded semaglutide across 2024 and 2025, and the warnings continue to expand.

This guide is the authentication checklist Filipino buyers should run before injecting any tirzepatide or branded semaglutide pen sourced outside a registered pharmacy. We cover the visual checks (hologram, packaging, lot number, branded pen click-count, label fonts), the documentation checks (FDA Philippines lot verification, the manufacturer and the manufacturer batch records), what counterfeits commonly contain when tested in independent labs, and why visual inspection alone is not enough.

For the broader pricing context that drives the counterfeit market, see Tirzepatide Philippines complete guide. For the side-effect signature of authentic versus counterfeit GLP-1 product, see tirzepatide side effects.

Visual authentication: what authentic branded tirzepatide and branded semaglutide pens look like

the branded tirzepatide pen (tirzepatide, the manufacturer)

The the branded tirzepatide pen is a single-strength, four-dose disposable injector. Authentic units have:

• Holographic seal on the outer carton. The hologram shifts iridescent green to blue when tilted. Counterfeits often print a flat foil sticker that does not change colour.
• the manufacturer batch code printed on the carton and the pen itself. The batch code on the carton must match the batch code on the pen body.
• Specific colour-coding by strength. 2.5 mg is white. 5 mg is light blue. 7.5 mg is medium blue. 10 mg is dark blue. 12.5 mg is teal. 15 mg is grey-blue. Counterfeits sometimes have inconsistent colour or wrong colour for the labelled dose.
• Embossed the manufacturer logo on the pen body. Look for crisp embossing, not a flat printed logo.
• Click-count audible during dose dialling. Each click corresponds to a specific increment. Counterfeit pens often dial silently or with the wrong number of clicks per millilitre.
• Specific font for "branded tirzepatide" wordmark. the manufacturer uses a custom typeface; counterfeits frequently use Helvetica or Arial.
• Expiration date in MM/YYYY format. A pen with expiration outside the typical 24-month manufacture-to-expiry window is suspicious.

For the side-by-side product photos and the branded tirzepatide-specific authentication checks, see our branded tirzepatide Philippines guide.

the branded semaglutide pen (semaglutide, the manufacturer)

The the branded semaglutide pen is a multi-dose disposable injector available in 0.25/0.5 mg, 1 mg, and 2 mg strengths. Authentic units have:

• Holographic seal on the carton. the manufacturer uses a circular hologram with the company logo.
• Lot number printed on carton, pen, and the cartridge inside the pen. All three must match.
• Crisp embossing on the cap and pen body. Counterfeits often have shallow or uneven embossing.
• Specific colour-coding. The 0.25/0.5 mg pen is light blue. The 1 mg pen is light blue with a different cap design. The 2 mg pen is teal. Counterfeits sometimes mix up colours.
• Dose window clarity. The dose window on a real branded semaglutide pen displays clearly with no smudging. Cheap counterfeit pens often have poor dose-window manufacturing with smudged or unclear numerals.
• Manufactured in Denmark or France. Country of manufacture is printed on the carton.

For the branded semaglutide-specific market context, see our branded semaglutide Philippines complete guide.

Documentation authentication: FDA Philippines and manufacturer batch records

FDA Philippines lot verification

FDA Philippines maintains a public registry of approved pharmaceutical batches, including branded tirzepatide and branded semaglutide where registered. Batches that have been recalled or flagged are listed in FDA Advisories.

Procedure:

1. Locate the lot number on the carton and pen.
2. Visit fda.gov.ph/advisories.
3. Search for the brand name and lot number.
4. Confirm the lot is not subject to a recall or counterfeit advisory.

This check does not confirm authenticity (a counterfeit batch number that happens not to match a recalled lot looks fine here). It only filters out lots already flagged. Use it as a screening step, not a definitive authentication.

Manufacturer batch records

the manufacturer publishes batch authentication tools at the manufacturer.com (and via the regional the manufacturer distributor for the Philippines). the manufacturer does the same at novonordisk.com.

For the most rigorous check, the brand owner is the only entity that can authoritatively confirm a specific batch was produced by them. Customer service contact at the regional the manufacturer or the manufacturer office can confirm batch authenticity if you supply lot number, manufacture date, and the country the product was sourced from.

What counterfeit pens contain when tested

Independent laboratory analysis of seized or submitted counterfeit branded tirzepatide and branded semaglutide pens, published by international independent laboratories and national pharmacovigilance agencies, shows a consistent pattern.

Pattern 1: Underdosed authentic API. The pen contains real tirzepatide or semaglutide, but at 30 to 60 percent of the labelled dose. The user perceives weight loss because the active ingredient is real, but the curve is slower and less dramatic than expected. Often the side-effect intensity is also lower, which the user may interpret as "tolerating it well."

Pattern 2: Wrong-API substitution. A pen labelled tirzepatide contains semaglutide, or a pen labelled branded semaglutide contains liraglutide. The user perceives weight loss but on a different pharmacological profile. Side effects may not match what the user expects from the labelled drug.

Pattern 3: No active API. The pen contains bacteriostatic water, normal saline, or a glycerol-based diluent with no active ingredient. The user injects placebo. Weight loss does not occur, or occurs only through coincidental caloric restriction. The user often blames "low responder" status rather than counterfeit product.

Pattern 4: Adulterated with non-pharmaceutical compounds. Documented cases include cooking oils, motor oil base, and in extreme cases unknown substances that produced injection-site reactions and systemic symptoms. This is the highest-harm pattern.

Pattern 5: Authentic API contaminated. Real semaglutide or tirzepatide manufactured under poor sterility conditions, with endotoxin levels above the 0.5 EU/mg injectable limit or microbial counts above USP 61 thresholds. The active ingredient is correct, but injection causes systemic inflammatory response.

The frequency distribution across these patterns varies by source country, supply chain, and time period. Pattern 1 (underdosed) is the most common in well-organised counterfeit operations because it produces the appearance of efficacy and lowest customer complaints. Pattern 3 (no API) is the cheapest to manufacture and most common in opportunistic counterfeit operations.

What lab testing reveals that visual inspection cannot

Visual inspection catches the cheap counterfeits, the ones with mismatched holograms, wrong fonts, silent dialling, and obvious packaging errors. Visual inspection does not catch:

• Underdosing of authentic API. A pen with real tirzepatide at half the labelled dose looks identical to a properly dosed pen. The chromatogram tells you the dose; visual inspection cannot.
• Wrong-API substitution. A pen labelled tirzepatide with semaglutide inside looks identical to a real branded tirzepatide. Mass spectrometry tells you the molecule; visual inspection cannot.
• Sterility and endotoxin failures. A correctly labelled, correctly dosed pen contaminated during manufacture looks identical to a clean pen. LAL endotoxin testing and USP 61 microbial limits tell you the contamination level; visual inspection cannot.

This is the structural reason laboratory analysis exists. The visual checks filter the obvious counterfeits. The sophisticated counterfeits, particularly Pattern 1 (underdosed authentic) and Pattern 5 (contaminated authentic), require analytical chemistry to detect.

For the technical methodology, see how peptide testing works. For why a vendor-supplied COA does not solve this problem, see why vendor COAs cannot be trusted.

The Lumen Labs authentication test

Lumen Labs runs the standard authentication panel for branded tirzepatide, branded semaglutide, and other GLP-1 receptor agonist pens:

1. HPLC purity at the relevant absorbance wavelength.
2. LC-MS identity confirmation against the published molecular mass of tirzepatide (4813.5 Da) or semaglutide (4113.6 Da).
3. Quantitation in milligrams per millilitre, against the labelled dose.
4. Optional endotoxin (LAL) and microbial limits (USP 61) for the contamination question, recommended for any pen sourced through grey-market channels.

The output is a certificate of analysis with the methodology named, measured values reported with uncertainty range, and a verification key so the document cannot be forged. Each test result also fits one of five outcome categories matching the counterfeit patterns above:

• Pass: identity confirmed, quantitation within 5 percent of label, contamination within limits.
• Underdosed: identity confirmed, quantitation 10 percent or more below label.
• Wrong API: a different molecule than labelled.
• No API: no active ingredient detectable.
• Contaminated: identity and quantitation correct but contamination above limits.

For a single pen, testing costs approximately USD 80 to 150 (PHP 4,500 to 8,500). For a Filipino buyer purchasing multiple pens from a single source, one test validates or invalidates the entire supply chain at that vendor.

The economics of why Lumen Labs makes sense

A worked example from the Philippine grey market, using current 2026 pricing.

Scenario: Filipino buyer planning to use branded tirzepatide 5 mg for six months, four pens at PHP 22,000 from major retail pharmacies (PHP 88,000 total) versus four pens at PHP 9,000 from an online seller (PHP 36,000 total).

The price differential is PHP 52,000. The cost of one Lumen Labs authentication test on the first online pen: PHP 6,000.

If the online pen tests authentic and properly dosed, the buyer has saved PHP 46,000 over six months on the same medication. The savings recur on subsequent supply cycles.

If the online pen tests as underdosed, wrong API, no API, or contaminated, the buyer has spent PHP 15,000 (one PHP 9,000 pen plus PHP 6,000 test) to learn the source is unreliable. The next four months' worth of medication can be sourced through major retail pharmacies at the validated retail price, and no time was wasted on injecting an unknown substance.

The expected value of testing is positive across any reasonable distribution of outcomes. The cost of not testing, when the source turns out to be counterfeit, includes both the financial loss and the health risk of injection.

Bottom line on counterfeit GLP-1 in the Philippines

Counterfeit branded tirzepatide and branded semaglutide pens are documented in the Philippine market. The visual checks (hologram, lot number, embossing, dose-window clarity, packaging colour) catch the obvious counterfeits and should be the first filter. They do not catch the sophisticated counterfeits, particularly underdosed-authentic and contaminated-authentic patterns.

The only objective authentication for grey-market pens is independent third-party laboratory analysis. Lumen Labs is the Philippine peer to an established international peptide-testing laboratory (Czechia) and another international laboratory (USA), and runs HPLC, mass spectrometry, endotoxin, and microbial methods on submitted samples. The cost is small relative to the price differential between major retail pharmacies and online sources, and small relative to the cost of injecting a counterfeit.

For the practical step of how to send a sample, see how to send a peptide sample to Lumen Labs.

Disclaimer: Lumen Labs provides chemical analysis of submitted samples for harm-reduction and quality-verification purposes. We are not a substitute for medical care. Tirzepatide and semaglutide are prescription medications; consult a qualified Philippine licensed physician before starting, adjusting, or stopping any therapy. Information reflects published case data and Philippine market observations as of early 2026.